Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has issued a correction disclosure regarding its pharmaceutical contract manufacturing agreement with Checkpoint Therapeutics, Inc., moving forward the contract end date from October 2, 2030, to December 17, 2024, following the completion of contract performance.
📊 [Key Disclosure Details & Financial Figures]
- Disclosure Title: (Correction) Single Sales and Supply Contract
- Original Filing Date: October 6, 2020
- Reason for Correction: Change in contract end date due to completion of contract performance
- Key Correction Items:
- Contract End Date: (Before) October 2, 2030 ➔ (After) December 17, 2024
- Contract Details (As Revised in Filing):
- Contract Classification & Title: Other Sales/Supply Contract (Pharmaceutical Contract Manufacturing Agreement)
- Contract Amount: KRW 22,934,104,200 (USD 19,713,000, applied exchange rate KRW 1,163.40 per USD on initial disclosure date Oct 6, 2020)
- Recent Annual Revenue: KRW 701,591,859,755 (Based on recent annual revenue at initial disclosure)
- Contract Amount to Revenue Ratio: 3.27%
- Counterparty: Checkpoint Therapeutics, Inc.
- Contract Period: October 2, 2020 – December 17, 2024
- Contract Date: October 6, 2020
- Disclosure Postponement Details: Not applicable (-)
- Other Important Details:
- This contract represents an additional manufacturing agreement under the initial contract disclosed on November 8, 2017.
- Upon successful development by the client, the confirmed contract amount could increase up to USD 97,257,000.
- Related Disclosure: October 06, 2020: Single Sales and Supply Contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verifying Contract Completion and Periodic Report Updates
This correction disclosure provides notice that the contract end date for the pharmaceutical contract manufacturing deal with Checkpoint Therapeutics, Inc. has been updated following the completion of contract performance.
Checking whether the completed contract status is updated in upcoming periodic filings (Annual Report) is essential.
Relevant details can be verified in subsequent periodic filings and official disclosures.
📢 Disclaimer & Source Notice
Source: This content was structured and regenerated based on official data submitted to the Financial Supervisory Service’s DART system.
Investment Risk Warning: This content is provided solely for informational and educational purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
